Why the study?
The optimal timing of P2Y12 inhibitor administration in patients with STEMI transferred for primary PCI has not been completely elucidated.
Population
1,624 STEMI patients transferred for primary PCI within a regional STEMI network
Comparison
P2Y12 inhibitor pretreatment before coronary angiography vs administration in the catheterization laboratory
Design
Prospective multicenter registry analysis
Follow-up
30 days
Answers are grounded in this paper and cite their sources.
Multicenter registry study shows P2Y12 inhibitor pretreatment reduces 30-day cardiac events in transferred STEMI patients, indicating clinical benefit when given over 80 minutes before PCI.
BACKGROUND The optimal timing of P2Y12 inhibitor administration in patients with ST-segment elevation myocardial infarction (STEMI) has not been completely elucidating. OBJECTIVES This analysis from a prospective multicenter registry sought to assess the safety and effectiveness of P2Y12 inhibitor pretreatment in patients transferred for primary percutaneous coronary intervention (PCI) within a regional STEMI network. METHODS Pretreatment was defined as P2Y12 inhibitor administration before coronary angiography. Endpoints were major adverse cardiac events (MACE), major bleeding, and net adverse clinical events, a composite of MACE or major bleeding, within 30 days of index admission. Association of P2Y12 inhibitor pretreatment with outcomes was modeled using doubly robust weighted estimators based on propensity score analysis. RESULTS Of 1,624 patients included, 1,033 received P2Y12 inhibitors before angiography and 591 in the catheterization laboratory (cath lab). The non-pretreated cohort more often had history of coronary artery disease and were more likely to receive antiplatelet therapy before the index admission. After adjustment for confounding and dependent censoring, pretreatment with P2Y12 inhibitors predicted lower risk of MACE (adjusted HR: 0.53; 95% CI: 0.37-0.76), without increasing bleeding risk (adjusted HR: 0.62; 95% CI: 0.36-1.05), resulting in superior net clinical benefit (adjusted HR: 0.47; 95% CI: 0.26-0.86) compared with in-cath lab administration of P2Y12 inhibitors. There was a significant treatment-by-time interaction for MACE risk, whereby the observed benefits of pretreatment only became apparent when time between P2Y12 inhibitor administration and PCI was longer than 80 minutes. CONCLUSIONS In contemporary patients with STEMI transferred for primary PCI, pretreatment with P2Y12 inhibitors was associated with a significant time-dependent reduction of 30-day MACE without increasing bleeding risk.
No takes yet. Share an insight, caveat, or question.
Almendro‐Delia et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: